Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for 2'-Fucosyllactose.
A human milk oligosaccharide (HMO) that functions as a prebiotic and decoy receptor to modulate gut microbiota composition and inhibit pathogen adhesion to the intestinal epithelium.
119538
913.0 g/mol
-3.9
12-[2,3-dihydroxy-2-(hydroxymethyl)propyl]-22,23-dihydroxy-6-(1-hydroxyethyl)-3-(hydroxymethyl)-18-methyl-15-[(2-methylsulfonyl-1H-indol-3-yl)methyl]-9-propan-2-yl-1,4,7,10,13,16,19-heptazabicyclo[19.3.0]tetracosane-2,5,8,11,14,17,20-heptone
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for 2'-Fucosyllactose across standard consumer modalities.
High hygroscopicity of 2'-FL requires moisture-resistant HPMC capsules and desiccants to prevent clumping or degradation.
The high inclusion levels required for clinical efficacy can interfere with pectin gelation and result in a sticky, unstable texture.
Significant dosage requirements typically exceeding 200mg per serving surpass the limited payload capacity of standard thin-film polymer matrices.
Ready to launch a product featuring 2'-Fucosyllactose? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your 2'-Fucosyllactose extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your 2'-Fucosyllactose payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation